Serial 98757000
Live / Applied — First extension granted (statement of use) (as of 08 Jan 2026)
What this means for you
Not registered yet, but its 18 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98757000
- Mark type
- Design / logo
- Filed
- 18 Sept 2024
- Published for opposition
- 20 May 2025
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 001 — Chemicals: Viruses, viral vectors, and viral constructs for use in the manufacture of pharmaceuticals for the treatment of neuromuscular diseases and disorders.
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viral vaccines and viral vectors vaccines for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
- Class 041 — Education and entertainment services: Medical training and teaching
- Class 044 — Medical, beauty and agricultural services: Medical services; providing health information
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 09 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jan 2026 — SOU EXTENSION 1 GRANTED
- 08 Jan 2026 — SOU EXTENSION 1 FILED
- 08 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 May 2025 — PUBLISHED FOR OPPOSITION
- 14 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Apr 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 31 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 31 Mar 2025 — NON-FINAL ACTION E-MAILED
- 31 Mar 2025 — NON-FINAL ACTION WRITTEN